Femoral fracture and atypical subtrochanteric fracture are thought to be uncommon side effects of long-term bisphosphonate treatment. Delay in bone healing may be caused by a decreased rate of bone turnover. Limited research has shown that teriparatide therapy may counteract the effects of bisphosphonates and promote bone repair. Methods: A retrospective assessment of individuals with atypical subtrochanteric and femoral fractures associated with the use of bisphosphonates were examined. There were 18 female patients signed up. The characteristics of an unusual fracture were congruent with the radiographic findings. All underwent surgical intervention, and teriparatide usage was suggested after surgery. Perioperative results, clinical, and radiographic outcomes were all considered outcome indicators.